Assenagon Asset Management S.A. Sells 126,633 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Assenagon Asset Management S.A. cut its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 35.2% during the first quarter, HoldingsChannel.com reports. The firm owned 232,947 shares of the biotechnology company’s stock after selling 126,633 shares during the quarter. Assenagon Asset Management S.A.’s holdings in BioCryst Pharmaceuticals were worth $2,218,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Phocas Financial Corp. bought a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at $1,956,000. Vanguard Group Inc. boosted its position in BioCryst Pharmaceuticals by 6.1% during the third quarter. Vanguard Group Inc. now owns 21,790,881 shares of the biotechnology company’s stock worth $165,393,000 after purchasing an additional 1,246,633 shares during the period. Aberdeen Group plc bought a new position in BioCryst Pharmaceuticals during the fourth quarter worth $7,126,000. BNP Paribas Financial Markets increased its holdings in shares of BioCryst Pharmaceuticals by 21.4% in the fourth quarter. BNP Paribas Financial Markets now owns 2,542,714 shares of the biotechnology company’s stock valued at $19,833,000 after purchasing an additional 448,436 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al raised its position in shares of BioCryst Pharmaceuticals by 106.5% in the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 233,354 shares of the biotechnology company’s stock valued at $1,820,000 after purchasing an additional 120,350 shares during the period. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX opened at $10.00 on Wednesday. The company has a market cap of $2.54 billion, a PE ratio of -5.62 and a beta of 0.57. BioCryst Pharmaceuticals, Inc. has a one year low of $6.00 and a one year high of $10.94. The firm’s 50 day simple moving average is $8.91 and its 200 day simple moving average is $8.29.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). The firm had revenue of $156.41 million for the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.BioCryst Pharmaceuticals’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.20 EPS. Equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.66 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on BCRX. HC Wainwright reaffirmed a “buy” rating and set a $32.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday. Weiss Ratings reissued a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Wall Street Zen downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Citizens Jmp upped their price objective on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a report on Thursday, May 7th. Finally, Cantor Fitzgerald increased their price objective on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Tuesday. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $21.67.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.